The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition
Maria Moreno‐Lopez(Inserm), Chiara Saponaro(University of Pisa), Ana Acosta‐Montalvo(Inserm), Nathalie Delalleau(Inserm), Valéry Gmyr(Inserm), Isaline Louvet(Inserm), Gianni Pasquetti(Inserm), Julie Kerr‐Conte(Inserm), Caroline Bonner(Inserm), Julien Thévenet(Inserm), François Pattou(Inserm)
Cited by 4
Related Papers
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
|Nutrients|2015|530
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
|Nature Medicine|2024|153
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
|Current Diabetes Reports|2015|145
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
|Cell Metabolism|2022|124